Nelipak® Corporation (“Nelipak”), a leading global provider of healthcare packaging solutions, announced the opening of its new Asi...
Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule ...
Meiji Seika Pharma Co., Ltd. announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodieste...
Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its co...
Cloud-based AI application for colorectal cancer prevention: Enhancing detection of clinically significant lesions without compromising safety and workfl...
Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% atActual Exchange Rates (AER); Impact of VYVANSE® Generics is T...
Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...
-Japan Tissue Engineering Co., Ltd.（J-TEC） announced that JACC, its autologous cultured cartilage product, has been granted approval by Japan’s N...
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing fo...
Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU in combination with pertuzumab significant...
Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China New...
International medical technology and cybersecurity company Sectra (STO: SECT B), in collaboration with distribution partner Matsunami Glass has comm...
PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibroste...
Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two...
© 2026 Biopharma Boardroom. All Rights Reserved.
